Cite
HARVARD Citation
Shah, P. et al. (2017). Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. Lipids in health and disease. 16 (1), pp. 1-12. [Online].